#CaplinPointLab Ltd Created a New 52Week High of 2425.00 on #NSE & 2424.00 on #BSE Today #StockToWatch #StockInNews #StockInFocus #StockMarket #Nifty #NSE #BSE #Nifty50 #Sensex

#CaplinPointLab Ltd Created a New 52Week High of 2409.00 on #NSE & 2407.20 on #BSE Today #StockToWatch #StockInNews #StockInFocus #StockMarket #Nifty #NSE #BSE #Nifty50 #Sensex

🚀 Top Stocks - Golden Cross 🤞 A Golden Crossover occurs when the 50-DMA moves above the 200-DMA, often signaling a potential long-term bullish trend🔥 🔖 Bookmark - DYOR - No Reco 🙏 #CaplinPointLab #SanofiConsumer #BancoProducts #HindustanFoods #PanamaPetrochem #InsecticidesIndia ✅ Strong promoter holding ✅ Positive technical momentum 📊 Golden Cross doesn't guarantee returns, but it often attracts momentum and institutional interest. Follow us for more insight 👍 👍 #StockMarketIndia #NSE #BSE #Investing #SwingTrading #GiftNifty #GoldenCross #StocksToWatch #MarketWatch @n_stox #FiiDii

5 Feb Result Analysis 📊 Full breakdown 👇 💎 LARGE CAPS (> ₹20,000 Cr) 🟢 Strong Performers #IOCL → PAT 695% YoY | 65% QoQ → GRMs printing money #PowerFinCorp → Steady 8% growth → consistency wins #HindustanCopper → Profit 149% → volume price tailwind #SuzlonEnergy → Sales 42% → ops firing (ignore tax noise) #UnoMinda → PAT 28% → auto-ancillary recovery leader #ForceMotors → Profit 121% → premium CV margins expanding #HexawareTech → Stable 14% PAT → resilient IT play #InventurusKnowl → 41% PAT → niche scaling beautifully 🔴 Weak Spots #MaxHealthcare → PAT -38% QoQ → margin pressure #CumminsIndia → Double miss (Sales PAT ↓) #TimkenIndia → Sales up, margins crushed #GodrejPropert → Sales -49% → execution concerns 🚀 MID CAPS (₹5k–20k Cr) — Where the REAL money is 🟢 Momentum Turnarounds #PVRInox → PAT 261% → merger synergies kicking in #CCLProducts → Sales & PAT 59% → coffee exports booming #JSWCement → Loss → ₹131 Cr profit → huge EBITDA swing #SaatvikGreen → PAT 144% → solar theme alive #MarksansPharma → steady compounding QoQ #YatharthHospit → 49% → occupancy highs #CenturyPlyboard → housing demand tailwind #MindaCorp → 36% → segment outperformance #LloydsEngineeri → 71% → strong margin expansion #VarrocEngineer → clean turnaround #KamaHoldings → 85% → subsidiary strength #CaplinPointLab / #FDC → consistent pharma plays #Blackbuck → improving logistics economics #TransportCorp → infra theme beneficiary 🔴 Caution #AlembicPharma → QoQ fatigue #PolyMedicure → margin pressure #Nava → energy costs hurting spreads #GallanttIspat → steel demand cooling

Caplin Point Lab Subsidiary received USFDA final approval for methylprednisolone acetate 40/80mg/mL ANDA; US sales ~$57.4M (12 months to Nov 2025). 🏆 Follow🔖 @subrata_minu #Investor #Niftycrash #OptionsTreding #Investing #Breaking #Nifty #BreakingNews #CaplinPointLab

#caplinpointlab no one is talking about 🤫. #timethemarket indicator is green. Closed above GL, above dynamic band. Trending upward, promoters FII Increasing stake. Have revenue from US, So look out for #TrumpTariffs , can make entry with small capital. CDMO theme n tailwinds

🚀 #CAPLINPOINTLAB ચીલીમાં ધમાકેદાર પ્રવેશ! 🇨🇱 કેપ્લિન પોઈન્ટ લેબોરેટરીઝે ચિલીની ફાર્મા કંપની નિયોએથિકલ્સ ચિલી સ્પા (Neoethicals Chile SpA) નું 100% સંપાદન કર્યું છે. 💊હાલ મા નિયોએથિકલ્સનો ધંધો: ચિલીમાં ફાર્માસ્યુટિકલ માર્કેટિંગ અને વિતરણ નો છે.

Caplin Steriles Limited, a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the USFDA for its Abbreviated New Drug Application Procainamide Hydrochloride Injection USP, 1g/10mL and 1g/2mL Vials #SEnews #CaplinPointLab To view this stock in StockEdge click here web.stockedge.com/share/capl…

Caplin Point Lab good results in Q2! Revenue growth accelerates ( 17.8% YoY) Operating profit jumps 20.4% YoY Net profit rises 12.7% YoY Operating margin expands to 34.1% #CaplinPointLab #MarketAnalysis

Caplin Point Lab - #CaplinPointLab Good QoQ and YoY performance with strong revenue growth and improved profit. Operating Revenue at 483; QoQ: 459 ( 5.2%), YoY: 410 ( 17.8%). Operating Profit at 165; QoQ: 152 ( 8.6%), YoY: 137 ( 20.4%). Net Profit at 130.8; QoQ: 124.9 ( 4.7%), YoY: 116.1 ( 12.7%). Operating Margin at 34.1%; QoQ: 33.1%, YoY: 33.5%.

#CaplinPoint Laboratories has posted an impressive Q2 FY25 performance with revenue from operations rising to ₹483.10 crore, marking a 17.8% YoY increase 📈. Total revenue for the quarter exceeded ₹500 crore, reflecting a 17% YoY growth. For H1 FY25, revenue reached ₹942.06 crore, while PAT hit a record ₹250 crore, largely fueled by growth in the Latin American market 🌎. Caplin’s oncology unit, Caplin One Labs, generated ₹12 crore in H1, expected to achieve profitability by FY25. Meanwhile, Caplin Steriles Limited (CSL) saw strong revenue growth driven by expanded capacity in Phase II and new ANDA launches. 💊 Check the full report at 🌐 onemetric.in. Like ❤️ and Retweet 🔄 if you loved our hard work! @CaplinPointLab #Pharma #Q2Results

#caplinpointlab after many days caught a decent move ...Although did not go full size because of choppy market condition -Focus on good earnings Large base with trending Sectors ...it helps making good money while market recovers

STOCK IN NEWS #beml #titagarh #dcxsystems #surajestate #electronicsmart #hitech #ongc #gmr airport #caplinpointlab

Caplin point continues to provide steady growth. The most consistent performer I found. #CaplinPointLab

Q1 FY25 #resultsrush is here! - 7th August 2024 1. #CaplinPointLab - #NetProfit 1.24B rupees vs 1.03B (YoY) - #Revenue 4.6B rupees vs 3.95B (YoY) - EBITDA 1.7B #rupees vs 1.39B (YoY) - #EBITDA 35.7% VS 34% (YoY)

CAPLIN STERILES GETS USFDA APPROVAL FOR EPHEDRINE SULFATE INJECTION USP ✅ #caplinpointlab #sabarisec

In case if you missed this analysis. Just for education purpose #Caplinpointlab #Caplin #Pharma @kuttrapali26

Why I like #Caplinpointlab My expected target = 3500INR.. Not a Financial Advise. I am sharing my analysis just for education purpose. Please feel free to advise your views. @kuttrapali26 your thoughts please. 🙏🙏

7. #CaplinPointLab - #NetProfit 1.2B rupees vs 1B (YoY) - #Revenue 4.5B rupees vs 3.9B (YoY) - EBITDA 1.45B #rupees vs 1.24B (YoY) - #EBITDA margin 32.04% vs 31.84% (YoY)

#caplinpointlab #StockToWatch #pharma A good move, short retracement and now in a narrow range near 10emas . 🚀🫶🏻 @okaymanish